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A series of quinoline incorporated 2,4,5-trisubstituted imidazole derivatives (4a-h and 5a-f) have been synthesized. The 
structures of the synthesized compounds have been established by FT-IR, 1H NMR and mass spectral analysis. The prepared 
compounds have been evaluated for their in vitro antioxidant activity by DPPH method and antibacterial activity against 
Bacillus subtilis, Escherichia coli, Bacillus megaterium and Salmonella typhi bacterial strains at 500 µg/mL concentration. 
The compounds 4a, 4e and 4d exhibit good antioxidant activity. Among the synthesized compounds, 4a has shown 
significant antibacterial activity against all the three tested microorganisms. 
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Present scenario imidazole based scaffolds are very 
important synthetic intermediates for the synthesis of 
useful chemical compounds to tackle various diseases. 
The imidazole ring is an essential part of many natural 
compounds such as histidine and histamine. Imidazole 
and its derivatives have occupied a unique place in the 
field of medicinal and agrochemical industries. 
Currently using drugs have made up of imidazole ring 
as a core moiety. Imidazole containing molecules i.e. 
tioconazole, sertaconazole, clotrimazole and 
bifonazole are effective antifungal drugs, whereas 
metronidazole and nimorazole are antibacterial drugs. 
Imidazole derivatives found to possess various 



























On the other hand, quinoline derivatives have gained 
considerable attention because of their wide range of 
applications. The quinoline is found in many naturally 
occurring alkaloids. Quinine is an antimalarial drug and 
has been isolated from the bark of cinchona trees. Many 
synthetic drugs used for the treatment of malaria such as 
chloroquin, plasmoquin and atebrin containing quinoline 
as an essential component. Quinoline ring is also present 
in commercially available dye cyanin. Apart from the 
above quinoline derivatives have been found to possess 




















The major problem of existing antimicrobial drugs 
for the treatment of microbial diseases is due to their 
side effects and also some microorganisms acquiring 
resistance against present drugs. In order to overcome 
this current situation, it is necessary to search for the 
new antimicrobial agents. Considering the bio-profile 
of imidazole and quinoline derivatives a series of 
quinoline containing 2,4,5-trisubstituted imidazole 
derivatives were synthesized and evaluated for their 
antioxidant and antibacterial activities. 
Results and Discussion 
Chemistry 
In the present work a series of quinoline containing 
substituted imidazole derivatives have been 
synthesized. The synthetic route for the final targeted 
compounds is shown in the reaction Scheme I. 
Intermediate 2-chloroquinoline-3-carbaldehyde (2) 
was synthesized using Vilsmeier-Haack reagent from 
acetanilide. 2-Hydroxy-quinoline-3-carbaldehyde (3) 
was prepared by heating the 2-chloroquinoline-3-
carbaldehyde (2) with 70% acetic acid. The title 
compounds were successfully achieved by the 
condensation of 2-chloroquinoline-3-carbaldehyde or 




2-hydroxyquinoline-3-carbaldehyde, substituted benzil 
and CH3COONH4 in presence of acetic acid. All the 
synthesized quinoline-imidazoles were characterized 
by spectral analysis. The compound 4a showed FT-IR 
stretching frequencies of 3327.6 cm
-1 
for N-H bond, 
1605.4 cm
-1 
for C=C and 1579.4 cm
-1 
for C=N bonds 
of imidazole ring. The 
1
H NMR spectrum of the 
compound 4a in DMSO-d6 solvent showed two 
singlet at (δ 3.70 and 3.73 ppm) corresponds to –
OCH3 group, singlet at δ 12.29 ppm for -OH and 
singlet at δ 12.41 ppm for imidazole NH. The 
aromatic protons of the compound 4a were appeared 
in the range 6.85 to 8.81 ppm. The structure 4a was 
further confirmed by mass spectral data which 
showed m/z value at 424.34 and which corresponds to 
M+1 ion. Similarly, all other compounds 4b-h and 
5a-f was characterized. 
 
Antioxidant activity 
Antioxidant activity of the synthesized quinoline 
incorporated 2,4,5-trisubstituted imidazole derivatives 
4a-h and 5a-f were carried out using DPPH free 
radical scavenging assay method. Among the 
synthesized compounds 4d with methoxy group 4c 
and 4g with chloro group showed good antioxidant 
activity. The compound 5e with benzene ring showed 
significant activity. The antioxidant activity results of 
(4a-h) and (5a-f) is given in Figure 1. 
 
 




Figure 1 — Antioxidant activity of compounds 4a-h and 5a-f 
 





Antibacterial activity of the synthesized 
compounds 4a-h and 5a-f were determined using agar 
diffusion method. The compounds 4b, 4d and 4e 
exhibited considerable antibacterial activity against 
Bacillus subtilis, Escherichia coli, Bacillus 
megaterium and Salmonella typhi bacterial strains at 
500 µg/mL concentration as compared with drug 
ciprofloxacin. Among 5a-f series, 5a, 5c, 5d and 5e 
exhibited considerable activity against all the tested 
bacterial strains. Results of the antibacterial study are 
given in Table I. 
 
Materials and Methods 
All reagents used in the preparation of quinoline 
containing 2,4,5-trisubstituted imidazole derivatives 
were purchased from Sigma-Aldrich, USA. Solvents 
were purchased from S. D. Fine chemicals, India. The 
progress of the reaction and purity of the samples 
were checked by TLC using mobile phase petroleum 
ether and ethyl acetate (7:3). For TLC stationary 
phase, silica gel coated aluminium sheets (silica gel 
60 F254) procured from MERCK, India were 
employed. UV light is used to visualize the 
compounds spot on TLC plates. Column 
chromatography was used to purify the crude products 
and yields were recorded after the isolation. FT-IR 
spectra of the products were obtained on a JASCO 
FT-IR-4100 spectrophotometer using KBr pellet 
method. 
1
H NMR were recorded using JEOL  
500 MHz NMR instrument by using TMS as internal 
standard and chemical shift values are expressed in δ 
(ppm) scale. Melting points of the synthesized 
compounds were recorded by open capillary method 




2-Chloroquinoline-3-carbaldehyde 2 and 2-
hydroxyquinoline-3-carbaldehyde 3 were synthesized 




General synthetic procedure for the preparation of 
quinoline incorporated 2,4,5-trisubstituted imidazole 
derivatives 
Mixture of 2-hydroxyquinoline-3-carbaldehyde  
or 2-chloroquinoline-3-carbaldehyde (20 mmol), 
substituted benzil (20 mmol), CH3COONH4  
(100 mmol) and 100 mL of glacial acetic acid  
was refluxed for 8-13 h in a three necked round 
bottom flask. The progress of the reaction was 
monitored by TLC using mobile phase petroleum 
ether and ethyl acetate (7:3). After completion  
of the reaction, the mixture was poured into  
ice cold water. The solid compound precipitated was 
filtered and dried. The crude product was purified by 
column chromatography using petroleum ether and 
ethyl acetate. 
2-Chloroquinoline-3-carbaldehyde, 3: Off white 
solid. Mol. formula: C10H6ClNO. Yield 72%. 





H NMR (500 MHz, 
DMSO-d6): δ 7.75 (t, J = 7.2 Hz, 1H, ArH), 8.00 (t,J 
= 7.2 Hz, 1H, ArH), 8.05 (d, J = 8.3 Hz, 1H, ArH), 
8.30 (d, J = 8.3 Hz, 1H, ArH), 9.01 (s, 1H, ArH), 
10.39 (s, 1H, -CHO); MS: m/z Calcd 191.61. Found: 
192.16 [M+1]. 
2-Hydroxyquinoline-3-carbaldehyde, 4: Off 
white solid. Mol. formula: C10H7NO2. Yield 85%. 
m.p.248-250°C. FT-IR (KBr): 3362.3  (O-H), 3057.9  





(500 MHz, DMSO-d6): δ 7.23 (m, 1H, ArH), 7.36 (d, 
J = 8.5 Hz, 1H, ArH), 7.66 (m, 1H, ArH), 7.92 (m, 
1H, ArH), 8.51 (s, 1H, ArH) 10.24 (s, 1H, -CHO), 
12.23 (s, 1H, -OH); MS: m/z Calcd 173.16. Found: 
174.16 [M+1]. 
3-[4,5-bis(3-Methoxyphenyl)-1H-imidazol-2-yl] 
quinolin-2-ol, 4a: Pale yellow solid. Mol. formula: 
C26H21N3O3. Yield 78%. m.p.192-193°C. FT-IR 
Table I — Antibacterial activity of compounds 4a-h and 5a-f  
at 500 µg/mL concentration 
Compd Zone of inhibition (mm) 
S. typhi B. substilis B. megaterium E. coli 
4a 4.5 ±0..2 * * * 
4b 3.1±0.1 4.4±0.4 4.7±0.1 3.3±0.2 
4c * * * * 
4d 8.1±0.5 5.2±0.4 5.1±0.1 6.1±0.1 
4e 4.8±0.2 4.1±0.2 3.2±0.3 3.0±0.2 
4f * * * * 
4g * * * * 
4h * * * * 
5a 5.2±0.3 4.8±0.7 4.6±0.1 5.7±0.3 
5b * * * * 
5c 7.3±0.6 6.5±0.1 7.2±0.6 6.3±0.3 
5d 3.2±0.4 5.3±0.5 3.3±0.4 5.7±0.6 
5e 5.7±0.2 8.1±0.2 6.8±0.8 5.7±0.1 
5f * * * * 
a Ciprofloxacin 27.1±0.1 25.4±0.2 27.0±0.3 31.4±0.4 
a Reference standard ciprofloxacin at 25 µg/mL concentration 
*Compounds not showed inhibition at tested concentration 
 




(KBr): 3374.8 (N-H), 3058.6 (Ar-H), 1651.7 (C=C), 




H NMR (500 
MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 3.79 (s, 3H, 
-OCH3), 6.84 (d, J = 7.5 Hz, 1H, ArH), 6.87 (d, J = 
8.5 Hz, 1H, ArH), 7.08 (m, 1H, ArH), 7.13 (d, J = 7.5 
Hz, 1H, ArH), 7.27 (m, 6H, ArH), 7.53 (m, 1H, ArH), 
7.75 (d, J = 7.5 Hz, 1H, ArH), 9.01 (s, 1H, ArH), 
10.70 (s, 1H, OH), 12.03 (s, 1H, NH); MS: m/z Calcd 
423.46. Found: 424.12 [M+1]. 
3-[4,5-bis(4-Bromophenyl)-1H-imidazol-2-yl] 
quinolin-2-ol, 4b: Brown solid. Mol. formula: 
C24H15Br2N3O. Yield 81%. m.p.226-228°C. FT-IR 
(KBr): 3419.2 (N-H), 3061.4 (Ar-H), 1586.2 (C=C), 




H NMR (500 
MHz, DMSO-d6): δ 6.99  
(d, J = 9.0 Hz, 1H, ArH), 7.30 (m, 1H, ArH), 7.44  
(m, 2H, ArH), 7,52 (m, 2H, ArH), 7.58 (m, 1H, ArH), 
7.64 (dd, J = 6.9 Hz, 2.1 Hz, 2H, ArH), 7.87 (m, 2H, 
ArH), 7.94 (d, J = 6.9 Hz, 1H, ArH), 8.80 (s, 1H, 
ArH), 12.41 (s, 1H, OH), 12.42 (s, 1H, NH); MS: m/z 
Calcd 521.21. Found: 522.15 [M+1]. 
3-[4-(4-Chlorophenyl)-5-phenyl-1H-imidazol-2-yl] 
quinolin-2-ol, 4c: Pale yellow solid. Mol. formula: 
C24H16ClN3O. Yield 84%. m.p.221-223°C. FT-IR 
(KBr): 3451.2 (N-H), 3055.7 (Ar-H), 1617.0 (C=C), 




H NMR (500 
MHz, DMSO-d6): δ 7.26 (m, 6H, ArH), 7.50 (m, 3H, 
ArH), 7.58 (m, 3H, ArH), 7.94 (m, 1H, ArH), 8.81 (s, 
1H, ArH), 12.36 (s, 1H, OH), 12.42 (s, 1H, NH); MS: 
m/z Calcd 397.85. Found: 398.07 [M+1]. 
3-[4,5-bis(4-Methoxyphenyl)-1H-imidazol-2-yl] 
quinolin-2-ol, 4d: Pale brown solid. Mol. formula: 
C26H21N3O3.Yield 85%. m.p.206-208°C. FT-IR 
(KBr): 3418.2 (N-H), 3030.5 (Ar-H), 1611.2 (C=C), 




H NMR  
(500 MHz, DMSO-d6): δ 3.76 (s, 3H, -OCH3), 3.80 (s, 
3H, -OCH3), 6.80 (m, 4H, ArH), 7.27 (m, 1H, ArH), 
7.43 (d, J = 8.5 Hz, 2H, ArH), 7.55 (m, 2H, ArH), 
7.65 (d, J = 7.9 Hz, 2H, ArH), 7.74 (d, J = 7.5 Hz, 
1H, ArH) 8.96 (s, 1H, ArH), 10.34 (s, 1H, OH), 11.87 
(s, 1H, NH); MS: m/z Calcd 423.46. Found: 424.12 
[M+1]. 
3-(4,5-Diphenyl-1H-imidazol-2-yl)quinolin-2-ol, 4e: 
Yellow solid. Mol. formula: C24H17N3O. Yield 88%. 
m.p.281-283°C. FT-IR (KBr): 3321.8 (N-H), 3050.2 





H NMR (500 MHz, DMSO-d6): δ 7.27  
(m, 2H, ArH), 7.34 (m, 3H, ArH), 7.42 (t, J = 7.6 Hz, 
3H, ArH), 7.51 (m, 2H, ArH), 7.58 (m, 3H, ArH), 
7.93 (d, J = 7.6 Hz, 1H, ArH), 8.81 (s, 1H, ArH), 
12.30 (s, 1H, OH), 12.43 (s, 1H, NH); MS: m/z Calcd 
363.41. Found: 362.20 [M-1]. 
3-[4,5-bis(4-Methylphenyl)-1H-imidazol-2-yl] 
quinolin-2-ol, 4f: Pale yellow solid. Mol. formula: 
C26H21N3O. Yield 78%. m.p.240-241°C. FT-IR 
(KBr): 3341.1 (N-H), 3052.8 (Ar-H), 1615.1 (C=C), 




H NMR  
(500 MHz, DMSO-d6): δ 2.31 (s, 3H, -CH3), 2.34  
(s, 3H, -CH3), 7.14 (d, J = 8.3 Hz, 2H, ArH), 7.23  
(d, J = 7.6 Hz, 3H, ArH), 7.28 (m, 2H, ArH), 7.37  
(d, J = 8.3 Hz, 2H, ArH), 7.42 (d, J = 8.3 Hz,  
1H, ArH), 7.57 (m, 1H, ArH), 7.92 (d, J = 7.6 Hz, 1H, 
ArH), 8.79 (s, 1H, ArH), 12.20 (s, 1H, OH),  
12.42 (s, 1H, NH); MS: m/z Calcd 391.46. Found: 
392.11 [M+1]. 
3-[5-(2-Chlorophenyl)-4(3,4-dimethoxyphenyl)-
1H-imidazol-2-yl]quinolin-2-ol, 4g: Brown solid. 
Mol. formula: C26H20ClN3O3. Yield 80%. m.p.255-
258°C. FT-IR (KBr): 3542.6 (N-H), 3052.8 (Ar-H), 





NMR (500 MHz, DMSO-d6): δ 3.55 (s, 3H, -CH3), 
7.73 (s, 3H, -CH3), 6.90 (m, 2H, ArH), 7.04 (m, 1H, 
ArH), 7.28 (d, J = 7.8 Hz, 1H, ArH), 7.44 (m, 1H, 
ArH), 7.57 (m, 3H, ArH), 7.92 (d, J = 7.8 Hz, 3H, 
ArH), 8.79 (s, 1H, ArH), 12.37 (s, 1H, OH), 12.39  
(s, 1H, NH); MS: m/z Calcd 457.90. Found: 458.00 
[M+1]. 
3-[4,5-Di(furan-2-yl)-1H-imidazol-2-yl]quinolin-
2-ol, 4h: Brown solid. Mol. formula: C20H13N3O3; 
Yield:76%. m.p.248-250°C. FT-IR (KBr): 3417.1 (N-





H NMR (500 MHz, DMSO-d6): 
δ 7.30 (t, J = 7.4 Hz, 2H, ArH), 7.45 (d, J = 8.1 Hz, 
2H, ArH), 7.62 (m, 2H, ArH), 7.81 (m, 2H, ArH), 
7.95 (d, J = 7.3 Hz, 2H, ArH), 8.82 (s, 1H, ArH), 
12.41 (s, 1H, OH), 12.54 (s, 1H, NH); MS: m/z Calcd 
343.33. Found: 344.06 [M+1]. 
3-[4,5-bis(3-Methoxyphenyl)-1H-imidazol-2-yl]-
2-chloroquinoline, 5a: Pale yellow solid. Mol. 
formula: C26H20ClN3O2. Yield 65%. m.p.179-180°C. 
FT-IR (KBr): 3383.5 (N-H), 3064.3 (Ar-H), 1600.6 





(500 MHz, DMSO-d6): δ 3.69 (s, 3H, -OCH3), 3.75 (s, 
3H, -OCH3), 6.84 (m, 1H, ArH), 6.96 (dd, J = 9.0 Hz, 
2.1 Hz, 1H, ArH), 7.09 (d, J = 7.6 Hz, 2H, ArH), 7.18 
(d, J = 7.6 Hz, 2H, ArH), 7.25 (t, J = 7.9 Hz 1H, 
ArH), 7.37 (t, J = 7.9 Hz, 1H, ArH), 7.74 (t, J = 7.6 Hz, 
1H, ArH), 7.90 (t, J = 7.6 Hz, 1H, ArH), 8.05  




(d, J = 8.3 Hz, 1H, ArH), 8.15 (d, J = 7.6 Hz, 1H, 
ArH), 8.85 (s, 1H, ArH), 12.91 (s, 1H, NH); MS: m/z 
Calcd 441.9. Found: 442.34 [M+1]. 
3-[4,5-bis(4-Bromophenyl)-1H-imidazol-2-yl]-2-
chloroquinoline, 5b: Brown solid. Mol. formula: 
C24H14Br2ClN3. Yield 60%. m.p.232-235°C. FT-IR 
(KBr): 3330.5 (N-H), 3051.6 (Ar-H), 1609.1 (C=C), 




H NMR (500 MHz, 
DMSO-d6): δ 7.29 (d, J = 7.6 Hz, 1H, ArH), 7.44 (dd, 
J = 11 Hz, 8.3 Hz, 2H, ArH), 7.55 (m, 2H, ArH), 7.65 
(d, J = 9.0 Hz, 1H, ArH), 7.87 (m, 5H, ArH), 7.94 (d, 
J = 6.9 Hz, 1H, ArH), 8.80 (s, 1H, ArH), 12.43 (s, 1H 
NH); MS: m/z Calcd 539.64. Found: 540.83 [M+1]. 
2-Choro-3-[4-(4-chlorophenyl)-5-phenyl-1H-
imidazol-2-yl]quinoline, 5c: Pale yellow solid. Mol. 
formula: C24H15Cl2N3. Yield 65%. m.p.162-163°C. 
FT-IR (KBr): 3418.2 (N-H), 3063.4 (Ar-H), 1617.0 





(500 MHz, DMSO-d6): δ 7.31 (m, 2H, ArH), 7.41 (m, 
4H, ArH), 7.50 (m, 1H, ArH), 7.64 (m, 3H, ArH), 
7.78 (m, 1H, ArH), 7.96 (d, J = 7.9 Hz, 1H, ArH), 
8.04 (d, J = 8.4 Hz, 1H, ArH), 9.25 (d, J = 10.2 Hz, 
1H, ArH), 10.38 (s, 1H, NH); MS: m/z Calcd 416.2. 
Found: 418.24 [M+2]. 
3-[4,5-bis(4-Methoxyphenyl)-1H-imidazol-2-yl]-
2-chloroquinoline, 5d: Pale yellow solid. Mol. 
formula: C26H20ClN3O2. Yield 65%. m.p.148-150°C. 
FT-IR (KBr): 3418.2 (N-H), 3052.8 (Ar-H), 1613.2 





(500 MHz, DMSO-d6): δ 3.80 (s, 3H, -OCH3), 3.81 (s, 
3H, -OCH3), 7.26 (m, 1H, ArH), 6.88 (m, 1H, ArH), 
6.99 (m, 3H, ArH), 7.33 (d, J = 8.3 Hz, 1H, ArH), 
7.48 (m, 2H, ArH), 7.88 (m, 2H, ArH) 8.14 (m, 2H, 
ArH), 8.84 (s, 1H, ArH), 12.89 (s, 1H, NH); MS: m/z 
Calcd 441.90. Found: 442.34 [M+1]. 
2-Choro-3-[4,5-diphenyl-1H-imidazol-2-yl] 
quinoline, 5e: Pale yellow solid. Mol. formula: 
C24H16ClN3. Yield 68%. m.p.186-188°C. FT-IR 
(KBr): 3428.8 (N-H), 3062.4 (Ar-H), 1617.0 (C=C), 




H NMR (500 MHz, 
DMSO-d6): δ 7.26 (m, 1H, ArH), 7.33 (t, J = 7.6 Hz, 
2H, ArH), 7.40 (m, 1H, ArH), 7.46 (m, 2H, ArH), 
7.53 (m, 2H, ArH), 7.59 (d, J = 6.9 Hz, 2H, ArH), 
7.74 (t, J = 7.9 Hz, 1H, ArH), 7.90 (m, 1H, ArH), 8.04 
(d, J = 7.6 Hz, 1H, ArH), 8.15 (d, J = 7.6 Hz, 1H, 
ArH), 8.86 (s, 1H, ArH), 12.90 (s, 1H, NH); MS: m/z 
Calcd 381.85. Found: 382.29 [M+1]. 
3-[4,5-bis(4-Methylphenyl)-1H-imidazol-2-yl]-2-
chloroquinoline, 5f: Pale yellow solid. Mol. formula: 
C26H20ClN3. Yield 65%. m.p.163-165°C. FT-IR 
(KBr): 3397.0 (N-H), 3063.4 (ArH), 1616.5 (C=C), 




H NMR (500 MHz, 
DMSO-d6): δ 2.31 (s, 3H, -CH3), 2.33 (s, 3H, -CH3), 
7.21 (d, J = 67.5 Hz, 4H, ArH), 7.44 (d, J = 19.3 Hz, 
4H, ArH), 7.73 (t, J = 7.2 Hz, 1H, ArH), 7.89  
(t, J = 7.9 Hz, 1H, ArH), 8.03 (d, J = 8.3 Hz, 1H, 
ArH), 8.14 (d, J = 8.3 Hz, 1H, ArH), 8.84 (s, 1H, 
ArH), 12.78 (s, 1H, NH); MS: m/z Calcd 409.91. 
Found: 410.36 [M+1]. 
 
Antioxidant activity 
The antioxidant activity study of 4a-h and 5a-f 
were carried out by using DPPH method reported by 
Sunil et al.
31
 The different concentration of stock 
solutions (10, 50 and100 μg/mL) of synthesized 
compounds were prepared by using methanol. 0.1 mM 
1,1-diphenyl-2-picryl hydrazyl [DPPH] in methanol was 
added to the above stock solutions and mixed uniformly. 
The resulting solution was kept in dark for 20 minutes  
at room temperature. Then the absorbance of the test 
solution was measured at 517 nm taking a reference 
standard BHA. The percentage inhibition was 
calculated by the following formula. 
 
% Inhibition =





Antibacterial activity on Escherichia coli, Bacillus 
subtilis, Bacillus megaterium and Salmonella typhi 
was performed for 4a-h and 5a-f by using agar well 
diffusion method described by Perez et al.
32
 taking 
ciprofloxacin as a standard. Initially the bacterial 
cultures were incubated at 37°C for 18 h in a media. 
The agar plates in the media were prepared and on 
each agar plate previously incubated culture was 
spread uniformly. Then plates were allowed to keep it 
for 20 min and wells were filled with 500 µg/mL 
concentration of synthesized compounds. The 
diameter of zone inhibition (in mm) was recorded 
after the plates were incubated at 37°C for 24 h. 
 
Conclusions 
In this study, we have reported a series of  
2-hydroxyquinoline and 2-chloro-quinoline 
incorporated 2,4,5-trisubstituted imidazole derivatives 
through one-pot multi-component synthesis  
using 2-hydroxy quinoline-3-carbaldehyde (for 4a-h) 
or 2-chloroquinoline-3-carbaldehyde (for 5a-f), 
ammonium acetate and substituted benzil in the 
presence acetic acid with good yield. The yields in the 




range 61 to 88 % were obtained. All the synthesized 
quinoline containing imidazoles were characterized 
by FT-IR, 
1
H NMR and Mass spectra of analysis. The 
synthesized compounds exhibited good antioxidant 
activity at 10, 50, 100 µg/mL concentrations. It is 
found that antioxidant activity increases with the 
increase in compound concentration. Among the 
tested compounds the compounds 4c, 4g and 5e 
exhibited significant antioxidant activity. 
Antibacterial activity of compounds 4a-h and 5a-f 
against Bacillus subtilis, Escherichia coli, Bacillus 
megaterium and Salmonella typhi bacterial strains  
at 500 µg/mL concentration indicated that the 
compounds 5a-f series exhibited considerable 
antibacterial activity against tested bacterial strains. 
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